New Breast Cancer Clinical Data Accepted for Presentation at San Antonio Breast Cancer Symposium
August 23 2007 - 7:54AM
PR Newswire (US)
TORONTO, Aug. 23 /PRNewswire-FirstCall/ -- Predictive medicine
company PreMD Inc. (TSX: PMD; Amex: PME) today announced that an
abstract entitled, 'Galactose oxidase Schiff's reactivity is higher
in nipple aspirate fluid from cancerous breasts than from healthy
patients' has been accepted for presentation at the 30th Annual San
Antonio Breast Cancer Symposium (SABCS). The SABCS is a leading
international symposium for physicians and healthcare researchers
involved in breast cancer research. "We are extremely pleased and
honored that this abstract has been accepted for presentation at
this influential symposium," said Brent Norton, president and chief
executive officer of PreMD Inc. "This study provides valuable
clinical insight as to how women with unilateral breast cancer may
benefit from testing with galactose oxidase Schiff's (GOS)
reactivity. This presentation further strengthens our clinical data
and our entire cancer franchise, which we are progressively
developing." GOS reactivity is significantly different between
nipple aspirate fluid (NAF) taken from cancerous versus
non-cancerous breasts of women with unilateral breast cancer. This
study extends these findings and evaluates GOS reactivity in
healthy control patients. The lead author on the study is Dr. Anees
B. Chagpar from the University of Louisville. The San Antonio
Breast Cancer Symposium takes place on December 13-16, 2007, in San
Antonio, Texas. About PreMD Inc. PreMD Inc. is a leader in
predictive medicine, dedicated to developing rapid, non-invasive
tests for the early detection of life-threatening diseases. PreMD's
cardiovascular products are branded as PREVU(x) Skin Cholesterol
Test, to be marketed and distributed by AstraZeneca. The company's
cancer tests include ColorectAlert(TM), LungAlert(TM) and a breast
cancer test. PreMD's head office is located in Toronto, Ontario and
its research and product development facility is at McMaster
University in Hamilton, Ontario. For further information, please
visit http://www.premdinc.com/. For more information about
PREVU(x), please visit http://www.prevu.com/. This press release
contains forward-looking statements. These statements involve known
and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include,
among others, the success of a plan for regaining compliance with
certain continued listing standards of the American Stock Exchange,
successful development or marketing of the Company's products, the
competitiveness of the Company's products if successfully
commercialized, the lack of operating profit and availability of
funds and resources to pursue R&D projects, the successful and
timely completion of clinical studies, product liability, reliance
on third-party manufacturers, the ability of the Company to take
advantage of business opportunities, uncertainties related to the
regulatory process, and general changes in economic conditions. In
addition, while the Company routinely obtains patents for its
products and technology, the protection offered by the Company's
patents and patent applications may be challenged, invalidated or
circumvented by our competitors and there can be no guarantee of
our ability to obtain or maintain patent protection for our
products or product candidates. Investors should consult the
Company's quarterly and annual filings with the Canadian and U.S.
securities commissions for additional information on risks and
uncertainties relating to the forward-looking statements. Investors
are cautioned not to rely on these forward-looking statements.
PreMD is providing this information as of the date of this press
release and does not undertake any obligation to update any
forward-looking statements contained in this press release as a
result of new information, future events or otherwise. (x)
Trademark DATASOURCE: PreMD Inc. CONTACT: Brent Norton, President
and CEO, Tel: (416) 222-3449 ext. 22, Email: ; Ron Hosking, Vice
President Finance and CFO, Tel: (416) 222-3449 ext. 24, Email: ;
Michelle Rabba, Manager, Corporate Communications, Tel: (416)
222-3449 ext. 25, Email:
Copyright